Companies › Hutchmed
11 active drug programs in 38 registered trials: 24 Phase 2, 8 Phase 1, 5 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HMPL-306 IDH1/IDH2 inhibitor | IDH1, IDH2 | Phase 3 | Acute Myeloid Leukemia; Gliomas Harboring IDH1 and/or IDH2 Mutations | Dec 2026 |
| HMPL-760 TBK1 inhibitor | – | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Apr 2028 |
| fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Endometrial Cancer; Advanced Renal Cell Carcinoma | Jan 2029 |
| sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Advanced Endometrial Cancer; Advanced Renal Cell Carcinoma | Jan 2029 |
| Sovleplenib (HMPL-523) Tyrosine-protein kinase SYK inhibitor | SYK | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia | Nov 2026 |
| Surufatinib Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | FGFR1, FLT1, FLT4, KDR | Phase 2 | Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma … | May 2028 |
| Hmpl-453 (HMPL-453) Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor | FGFR1, FGFR2, FGFR3 | Phase 2 | Advanced Intrahepatic Cholangiocarcinoma | Jun 2028 |
| HMPL-506 | – | Phase 1 | Hematological Malignancies | Oct 2027 |
| HMPL-A251 HER2-targeting antibody-drug conjugate | – | Phase 1 | Solid Tumors, Adult | Nov 2028 |
| HMPL-A580 | – | Phase 1 | Solid Tumors, Adult | Dec 2028 |
| HMPL-A830 | – | Phase 1 | Solid Tumor, Adult | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05218889 | Surufatinib | Phase 1 | Pancreatic Cancer | Oncology | Dec 2024 |
| NCT06239532 | Surufatinib | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Dec 2024 |
| NCT05165407 | Surufatinib | Phase 2 | Neuroendocrine Neoplasm | Oncology | Sep 2025 |
| NCT05522231 | fruquintinib | Phase 2 | Advanced Renal Cell Carcinoma | Oncology | Aug 2026 |
| NCT05522231 | sintilimab | Phase 2 | Advanced Renal Cell Carcinoma | Oncology | Aug 2026 |
| NCT05535933 | Sovleplenib (HMPL-523) | Phase 2 | Warm Antibody Autoimmune Hemolytic Anemia | Hematology | Nov 2026 |
| NCT05106777 | Surufatinib | Phase 2 | Sarcoma | Oncology | Dec 2026 |
| NCT07025018 | HMPL-306 | Phase 1 | Gliomas Harboring IDH1 and/or IDH2 Mutations | Oncology | Dec 2026 |
| NCT05969171 | Surufatinib | Phase 2 | Pancreatic Cancer Metastatic | Oncology | Dec 2026 |
| NCT05481476 | Surufatinib | Phase 2 | Pancreatic Neoplasms | Oncology | Dec 2026 |
| NCT04922658 | Surufatinib | Phase 2 | Advanced Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05652283 | Surufatinib | Phase 2 | Ovarian Cancer | Oncology | Mar 2027 |
| NCT06708858 | Surufatinib | Phase 2 | Advanced Biliary Tract Cancer | Oncology | Jul 2027 |
| NCT05747729 | Surufatinib | Phase 1 | Neuroendocrine Carcinoma | Oncology | Jul 2027 |
| NCT07357623 | Surufatinib | Phase 2 | Pulmonary Neuroendocrine Tumor | Oncology | Sep 2027 |
| NCT06876844 | Surufatinib | Phase 2 | Head and Neck Cancer | Oncology | Sep 2027 |
| NCT06387082 | HMPL-506 | Phase 1 | Hematological Malignancies | Oncology | Oct 2027 |
| NCT05003037 | Surufatinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Nov 2027 |
| NCT07272512 | Surufatinib | Phase 4 | Neuroendocrine Tumors | Oncology | Nov 2027 |
| NCT05472948 | Surufatinib | Phase 2 | Adenocarcinoma of Small Intestine | Oncology | Dec 2027 |
| NCT07409428 | HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Oncology | Apr 2028 |
| NCT06361888 | Surufatinib | Phase 2 | Metastatic Pancreatic Cancer | Oncology | May 2028 |
| NCT04353375 | Hmpl-453 (HMPL-453) | Phase 2 | Advanced Intrahepatic Cholangiocarcinoma | Oncology | Jun 2028 |
| NCT07436741 | Surufatinib | Phase 3 | Pancreatic Cancer, Adult | Oncology | Sep 2028 |
| NCT06719700 | Surufatinib | Phase 2 | Toripalimab | Oncology | Nov 2028 |
| NCT07228247 | HMPL-A251 | Phase 1 | Solid Tumors, Adult | Oncology | Nov 2028 |
| NCT06387069 | HMPL-306 | Phase 3 | Acute Myeloid Leukemia | Oncology | Dec 2028 |
| NCT07396584 | HMPL-A580 | Phase 1 | Solid Tumors, Adult | Oncology | Dec 2028 |
| NCT06584032 | fruquintinib | Phase 3 | Advanced Endometrial Cancer | Oncology | Jan 2029 |
| NCT06584032 | sintilimab | Phase 3 | Advanced Endometrial Cancer | Oncology | Jan 2029 |
| NCT07718581 | HMPL-A830 | Phase 1 | Solid Tumor, Adult | Oncology | May 2029 |
| NCT06447636 | Surufatinib | Phase 2 | Gastric Cancer | Oncology | May 2029 |
| NCT07609121 | Surufatinib | Phase 2 | NSCLC (Non-small Cell Lung Cancer) | Oncology | May 2029 |
| NCT07086469 | Surufatinib | Phase 2 | Toripalimab | Oncology | Jul 2029 |
| NCT07086456 | Surufatinib | Phase 2 | Surufatinib | Oncology | Jul 2029 |
| NCT05839275 | Surufatinib | Phase 1 | High-Risk Localized Soft Tissue Sarcoma | Oncology | Jul 2029 |
| NCT07103395 | Surufatinib | Phase 2 | Lung Cancer (NSCLC) | Oncology | Dec 2029 |
| NCT07505472 | Surufatinib | Phase 2 | Rectal Cancer | Oncology | Dec 2029 |
Cash and short-term investments of $1.4bn on 2025-12-31; operating cash outflow about $65m a year; runway about 253 months at that burn, to Jan 2047; 6 of 6 coming phase 2-3 readouts fall inside that runway
Chipscreen Biosciences Nuvation Bio Ascentage Pharma Group Sellas Life Sciences Group Exelixis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.